A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B

被引:74
作者
Sonneveld, Milan J. [1 ]
Rijckborst, Vincent [1 ]
Boucher, Charles A. B. [2 ]
Zwang, Louwerens [3 ]
Beersma, Matthias F. C. [2 ]
Hansen, Bettina E. [1 ,4 ]
Janssen, Harry L. A. [1 ]
机构
[1] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr, Dept Virol, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr, Dept Clin Chem, Rotterdam, Netherlands
[4] Erasmus MC Univ Med Ctr, Dept Biostat, Rotterdam, Netherlands
关键词
Hepatitis B surface Antigen; Architect; Elecsys; Prediction of response; HBV genotype; PEGINTERFERON ALPHA-2A; HBSAG LEVELS; SUSTAINED RESPONSE; NATURAL-HISTORY; VIRUS; PREDICTION; QUANTITATION; PERSPECTIVE; DECLINE;
D O I
10.1016/j.jcv.2011.04.005
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Background and objectives: Serum Hepatitis B surface Antigen (HBsAg) levels correlate with hepatitis B virus intrahepatic covalently closed circular DNA and may predict response to treatment. Currently, 2 commercial platforms are available for HBsAg quantification in clinical practice, the Architect HBsAg QT and the Elecsys HBsAg. We aimed to directly compare the results of these assays. Study design: HBsAg levels were measured in 1427 serum samples from HBeAg-positive chronic hepatitis B patients who participated in a randomized trial of peginterferon alfa-2b +/- lamivudine. Samples were extracted from our serum bank, thawed, and subsequently analysed for HBsAg levels using both assays. Results: Of 1427 samples, 242 (17%) were taken before and 1185 during the treatment phase of the study. Distribution of HBV genotypes was 447 (31%) genotype A, 125 (9%) B, 210 (15%) C and 534 (37%) D. Correlation between Architect and Elecsys results was high (r = 0.96, p < 0.001). By Bland-Altman analysis, agreement between the two assays was close (mean difference between Architect and Elecsys: -0.01 log IU/mL, 95% CI: -0.55-0.52 log IU/mL), also when analysed separately for HBV genotypes A-D. Additionally, the performance of our recently published stopping rule for HBeAg-positive patients treated with peginterferon was comparable: the negative predictive values were 96% and 98% for Elecsys and Architect, respectively. Conclusions: There is a high correlation and close agreement between quantitative HBsAg measurements conducted with the Architect and the Elecsys. Clinical prediction rules derived from data from one platform can be applied on the other; both can therefore be used in clinical practice. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 178
页数:4
相关论文
共 22 条
[1]
Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers [J].
Brunetto, Maurizia Rossana ;
Oliveri, Filippo ;
Colombatto, Piero ;
Moriconi, Francesco ;
Ciccorossi, Pietro ;
Coco, Barbara ;
Romagnoli, Veronica ;
Cherubini, Beatrice ;
Moscato, Giovanna ;
Maina, Anna Maria ;
Cavallone, Daniela ;
Bonino, Ferruccio .
GASTROENTEROLOGY, 2010, 139 (02) :483-490
[2]
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B [J].
Brunetto, Maurizia Rossana ;
Moriconi, Francesco ;
Bonino, Ferruccio ;
Lau, George K. K. ;
Farci, Patrizia ;
Yurdaydin, Cihan ;
Piratvisuth, Teerha ;
Luo, Kanxian ;
Wang, Yuming ;
Hadziyannis, Stephanos ;
Wolf, Eva ;
McCloud, Philip ;
Batrla, Richard ;
Marcellin, Patrick .
HEPATOLOGY, 2009, 49 (04) :1141-1150
[3]
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response [J].
Chan, Henry Lik-Yuen ;
Wong, Vincent Wai-Sun ;
Tse, Ada Mei-Ling ;
Tse, Chi-Hang ;
Chim, Angel Mei-Ling ;
Chan, Hoi-Yun ;
Wong, Grace Lai-Hung ;
Sung, Joseph Jao-Yiu .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (12) :1462-1468
[4]
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay [J].
Deguchi, M ;
Yamashita, N ;
Kagita, M ;
Asari, S ;
Iwatani, Y ;
Tsuchida, T ;
Iinuma, K ;
Mushahwar, IK .
JOURNAL OF VIROLOGICAL METHODS, 2004, 115 (02) :217-222
[5]
Drug therapy - Hepatitis B virus infection [J].
Dienstag, Jules L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (14) :1486-1500
[6]
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years [J].
Fattovich, G. ;
Olivari, N. ;
Pasino, M. ;
D'Onofrio, M. ;
Martone, E. ;
Donato, F. .
GUT, 2008, 57 (01) :84-90
[7]
HEATHCOTE EJ, 2011, GASTROENTEROLOGY
[8]
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants [J].
Hussain, M ;
Chu, CJ ;
Sablon, E ;
Lok, ASF .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3699-3705
[9]
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised [J].
Janssen, HLA ;
van Zonneveld, M ;
Senturk, H ;
Zeuzem, S ;
Akarca, US ;
Cakaloglu, Y ;
Simon, C ;
So, TMJ ;
Gerken, G ;
de Man, RA ;
Niesters, HGM ;
Zondervan, P ;
Hansen, B ;
Schalm, SW .
LANCET, 2005, 365 (9454) :123-129
[10]
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective [J].
Jaroszewicz, Jerzy ;
Serrano, Beatriz Calle ;
Wursthorn, Karsten ;
Deterding, Katja ;
Schlue, Jerome ;
Raupach, Regina ;
Flisiak, Robert ;
Bock, C. -Thomas ;
Manns, Michael P. ;
Wedemeyer, Heiner ;
Cornberg, Markus .
JOURNAL OF HEPATOLOGY, 2010, 52 (04) :514-522